Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Parkinson's disease is one of the most well known neurodegenerative diseases. It is a chronic, progressive neurodegenerative disease characterized by both motor and nonmotor features. The disease has a significant clinical impact on patients, families, and caregivers through its progressive degenerative effects on mobility and muscle control.(1) An estimated 7 to 10 million people worldwide suffer from Parkinson's disease. antibodies-online offers a hand-picked number of antibodies, ELISA kits, recombinant proteins, as well as other tools for Parkinson's research.
Here you will find a list of important antibodies, reagents, kits, and other tools you need for your research in the field of Parkinson's disease, as well as some more additional resources on the topic.
The following targets are directly related to research on Parkinson's disease. Search Antibodies, Kits, Reagents and other products. Click on a gene to see the available products.
α-Synuclein is a presynaptic neuronal protein that is linked genetically and neuropathologically to Parkinson's disease (PD).(3) We offer a variety of reliable mono- and polyclonal SNCA antibodies.
We are preparing the requested document. Please wait, this may take a while...!
See all alpha-Synuclein Antibodies
As a promising target for neuroprotection strategies in PD, in vitro and in vivo models that accurately demonstrate LRRK2's function relevant to neurodegeneration will aide in the identification of molecules with the highest chance of success in the clinic.(4)
The DJ-1 gene is a causative gene for familial PD (park7) and also an oncogene. DJ-1 has various functions, including transcriptional regulation, antioxidative stress reaction, and chaperone, protease, and mitochondrial regulation.(5)
See all DJ-1 Antibodies
Here you will find a range of reliable ELISA kits with PubMed references for a number of PD related targets, which allow a quick and easy detection of proteins in biological samples. Click on the links to find more information.
(1) DeMaagd G, Philip A. Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. P T. 2015 Aug;40(8):504-32. PMID: 26236139; PMCID: PMC4517533.
(2) Emamzadeh, F. N., & Surguchov, A. (2018). Parkinson's Disease: Biomarkers, Treatment, and Risk Factors. Frontiers in neuroscience, 12, 612. doi:10.3389/fnins.2018.00612
(3) Stefanis L. α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. 2012 Feb;2(2):a009399. doi: 10.1101/cshperspect.a009399. PMID: 22355802; PMCID: PMC3281589.
(4) Webber PJ, West AB. LRRK2 in Parkinson's disease: function in cells and neurodegeneration. FEBS J. 2009 Nov;276(22):6436-44. doi: 10.1111/j.1742-4658.2009.07342.x.
(5) Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM. Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev. 2013;2013:683920. doi: 10.1155/2013/683920. Epub 2013 May 16. PMID: 23766857; PMCID: PMC3671546.